Roth Capital Downgrades CorMedix (CRMD) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq set for higher open as oil prices extend declines, midterm results awaited
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- Goldman data shows hedge funds cut leverage at fastest pace since March
Tweet
Share
E-mailGet Alerts CRMD Hot Sheet
Price: $5.39 --0%
Rating Summary:
11 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 12
Rating Summary:
11 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 12
Join SI Premium – FREE
Roth Capital downgraded CorMedix (NYSE: CRMD) from Buy to Neutral with a price target of $7.50 (from $2.50).
For an analyst ratings summary and ratings history on CorMedix click here. For more ratings news on CorMedix click here.
Shares of CorMedix closed at $7.60 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Essential Properties Realty Trust (EPRT) PT Lowered to $31 at Cantor Fitzgerald
- Napco Security Technologies, Inc. (NSSC) PT Lowered to $45 at DA Davidson
- Citi Downgrades Cogna Educacao SA (COGN3:BZ) to Sell
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
